🎉 M&A multiples are live!
Check it out!

Guardian Pharmacy Service Valuation Multiples

Discover revenue and EBITDA valuation multiples for Guardian Pharmacy Service and similar public comparables like Ramsay Health, Burjeel Holdings, and Compass Pathways.

Guardian Pharmacy Service Overview

About Guardian Pharmacy Service

Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.


Founded

2003

HQ

United States of America
Employees

3.4K+

Financials

LTM Revenue $1.3B

LTM EBITDA $93.2M

EV

$1.5B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Guardian Pharmacy Service Financials

Guardian Pharmacy Service has a last 12-month revenue of $1.3B and a last 12-month EBITDA of $93.2M.

In the most recent fiscal year, Guardian Pharmacy Service achieved revenue of $1.2B and an EBITDA of -$43.4M.

Guardian Pharmacy Service expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Guardian Pharmacy Service valuation multiples based on analyst estimates

Guardian Pharmacy Service P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $1.0B $1.2B XXX XXX XXX
Gross Profit $186M $208M XXX XXX XXX
Gross Margin 18% 17% XXX XXX XXX
EBITDA $58.8M -$43.4M XXX XXX XXX
EBITDA Margin 6% -4% XXX XXX XXX
Net Profit $35.4M $23.9M XXX XXX XXX
Net Margin 3% 2% XXX XXX XXX
Net Debt $30.3M $31.2M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Guardian Pharmacy Service Stock Performance

As of April 15, 2025, Guardian Pharmacy Service's stock price is $23.

Guardian Pharmacy Service has current market cap of $1.4B, and EV of $1.5B.

See Guardian Pharmacy Service trading valuation data

Guardian Pharmacy Service Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.5B $1.4B XXX XXX XXX XXX $-0.99

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Guardian Pharmacy Service Valuation Multiples

As of April 15, 2025, Guardian Pharmacy Service has market cap of $1.4B and EV of $1.5B.

Guardian Pharmacy Service's trades at 1.2x LTM EV/Revenue multiple, and 15.8x LTM EBITDA.

Analysts estimate Guardian Pharmacy Service's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Guardian Pharmacy Service and 10K+ public comps

Guardian Pharmacy Service Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.5B XXX XXX XXX
EV/Revenue 1.2x XXX XXX XXX
EV/EBITDA -33.9x XXX XXX XXX
P/E -16.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 35.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Guardian Pharmacy Service Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Guardian Pharmacy Service Valuation Multiples

Guardian Pharmacy Service's NTM/LTM revenue growth is 7%

Guardian Pharmacy Service's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Guardian Pharmacy Service's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Guardian Pharmacy Service's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Guardian Pharmacy Service and other 10K+ public comps

Guardian Pharmacy Service Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 17% XXX XXX XXX XXX
EBITDA Margin -4% XXX XXX XXX XXX
EBITDA Growth -174% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 4% XXX XXX XXX XXX
Revenue per Employee $0.4M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 25% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Guardian Pharmacy Service Public Comps

See public comps and valuation multiples for Hospitals & Clinics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Burjeel Holdings XXX XXX XXX XXX XXX XXX
PureHealth XXX XXX XXX XXX XXX XXX
Integral Diagnostics XXX XXX XXX XXX XXX XXX
Ramsay Health XXX XXX XXX XXX XXX XXX
Compass Pathways XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Guardian Pharmacy Service M&A and Investment Activity

Guardian Pharmacy Service acquired  XXX companies to date.

Last acquisition by Guardian Pharmacy Service was  XXXXXXXX, XXXXX XXXXX XXXXXX . Guardian Pharmacy Service acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Guardian Pharmacy Service

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Guardian Pharmacy Service

When was Guardian Pharmacy Service founded? Guardian Pharmacy Service was founded in 2003.
Where is Guardian Pharmacy Service headquartered? Guardian Pharmacy Service is headquartered in United States of America.
How many employees does Guardian Pharmacy Service have? As of today, Guardian Pharmacy Service has 3.4K+ employees.
Who is the CEO of Guardian Pharmacy Service? Guardian Pharmacy Service's CEO is Mr. Fred Burke.
Is Guardian Pharmacy Service publicy listed? Yes, Guardian Pharmacy Service is a public company listed on NYS.
What is the stock symbol of Guardian Pharmacy Service? Guardian Pharmacy Service trades under GRDN ticker.
When did Guardian Pharmacy Service go public? Guardian Pharmacy Service went public in 2024.
Who are competitors of Guardian Pharmacy Service? Similar companies to Guardian Pharmacy Service include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health.
What is the current market cap of Guardian Pharmacy Service? Guardian Pharmacy Service's current market cap is $1.4B
What is the current revenue of Guardian Pharmacy Service? Guardian Pharmacy Service's last 12-month revenue is $1.3B.
What is the current EBITDA of Guardian Pharmacy Service? Guardian Pharmacy Service's last 12-month EBITDA is $93.2M.
What is the current EV/Revenue multiple of Guardian Pharmacy Service? Current revenue multiple of Guardian Pharmacy Service is 1.2x.
What is the current EV/EBITDA multiple of Guardian Pharmacy Service? Current EBITDA multiple of Guardian Pharmacy Service is 15.8x.
What is the current revenue growth of Guardian Pharmacy Service? Guardian Pharmacy Service revenue growth between 2023 and 2024 was 17%.
Is Guardian Pharmacy Service profitable? Yes, Guardian Pharmacy Service is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.